Doctoral School of Health Sciences, Faculty of Health Science, University of Pecs, Vorosmarty Mihaly Str. 4, Pecs, 7621, Hungary.
Faculty of Business and Economics, University of Pecs, Pecs, Hungary.
Sci Rep. 2022 Dec 23;12(1):22262. doi: 10.1038/s41598-022-26824-5.
The development of effective, safe, and acceptable vaccines is a long process. COVID-19 vaccine hesitancy continues to elicit mixed reactions among different quarters despite numerous evidence of their effectiveness. This study aimed to determine the availability and acceptance rates of SARS-CoV-2 vaccines, among Kenyan and Hungarian residing populations and the underlying reasons contributing to the hesitancy of uptake. A non-probability, snowball sampling design was employed, and a survey questionnaire tool link was expeditiously disseminated. Data were carefully analyzed descriptively. Demographic variables, COVID-19 awareness, possible exposure, reasons associated with hesitancy in taking up a vaccine, choice of a vaccine, and availability of vaccines among other important variables were tested to explore their associations with vaccine acceptance rates between the two distinct countries. A total of 1960 participants were successfully enrolled in the research study, while 67 participants were excluded based on the inclusion criterion set. There was, however, no significant difference in COVID-19 public awareness between the Kenyan and Hungarian-residing participants, p = 0.300. Of the respondents, 62.4% were willing and ready to receive vaccines against COVID-19 disease. There was a significant difference (p = 0.014) between the Kenyan and Hungarian-residing respondents concerning vaccine uptake and acceptance rates. The vaccine acceptance rates in Hungary were higher than in Kenya, with mean = 0.27, SD = 0.446, S. E = 0.045 for the Hungarian population sample and mean = 0.40, SD = 0.492, S. E = 0.026, for the Kenyan sample respectively. Concerning gender and vaccine acceptance, there was a notable significant difference between males and females, p = 0.001, where the mean for males and females were 0.29 and 0.46 respectively. Acceptance rates among males were higher than among females. The functions of One-Way ANOVA and Chi-square were used to establish any significant differences and associations between means and variables respectively. Concerns regarding the safety, efficacy, and accuracy of information about the developed vaccines are significant factors that must be promptly addressed, to arrest crises revolving around COVID-19 vaccine hesitancy, especially in Kenya and among females in both populations, where acceptance rates were lower. Expansion of the screening program to incorporate antibody (serology) tests, is also highly recommended in the present circumstance. Equitable distribution of vaccines globally should be encouraged and promoted to adequately cover low- and middle-income countries. To enhance effective combat on vaccination hesitancy and apprehension in different countries, mitigation techniques unique to those countries must be adopted.
开发有效、安全和可接受的疫苗是一个漫长的过程。尽管有大量证据表明 COVID-19 疫苗有效,但 COVID-19 疫苗犹豫情绪在不同群体中仍存在分歧。本研究旨在确定肯尼亚和匈牙利居住人群中 SARS-CoV-2 疫苗的可及性和接受率,以及导致疫苗接种犹豫的潜在原因。采用非概率雪球抽样设计,并迅速传播调查问卷调查工具链接。数据经过仔细的描述性分析。人口统计学变量、COVID-19 意识、可能的暴露、与接种疫苗犹豫不决相关的原因、疫苗选择以及其他重要变量的疫苗可用性,以探索它们与两国之间疫苗接受率的关联。共有 1960 名参与者成功参加了这项研究,而根据设定的纳入标准,有 67 名参与者被排除在外。然而,肯尼亚和匈牙利居住的参与者对 COVID-19 的公众意识没有显著差异,p=0.300。在回答者中,62.4%的人愿意并准备接受 COVID-19 疾病疫苗。肯尼亚和匈牙利居住的受访者在疫苗接种和接受率方面存在显著差异(p=0.014)。匈牙利的疫苗接种率高于肯尼亚,匈牙利人群样本的平均值为 0.27,标准差为 0.446,标准误为 0.045,肯尼亚样本的平均值为 0.40,标准差为 0.492,标准误为 0.026。关于性别和疫苗接种,男性和女性之间存在显著差异,p=0.001,男性和女性的平均值分别为 0.29 和 0.46。男性的接种率高于女性。单因素方差分析和卡方检验的功能分别用于确定平均值和变量之间的任何显著差异和关联。对疫苗开发安全性、有效性和信息准确性的担忧是必须迅速解决的重要因素,以阻止围绕 COVID-19 疫苗犹豫的危机,特别是在肯尼亚和两个群体中的女性中,接种率较低。在当前情况下,强烈建议扩大筛选计划,纳入抗体(血清学)检测。应鼓励和促进全球疫苗的公平分配,以充分覆盖低收入和中等收入国家。为了加强不同国家对疫苗接种犹豫和担忧的有效打击,必须采用针对这些国家的缓解技术。